Metropolitan Life Insurance Company (MetLife)’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-20,221
| Closed | -$483K | – | 2954 |
|
|
2021
Q1 | $483K | Sell |
20,221
-1,017
| -5% | -$18.9K | 0.01% | 1441 |
|
|
2020
Q4 | $310K | Hold |
21,238
| – | – | ﹤0.01% | 1662 |
|
|
2020
Q3 | $302K | Hold |
21,238
| – | – | 0.01% | 1538 |
|
|
2020
Q2 | $312K | Buy |
21,238
+2,135
| +11% | +$21.7K | 0.01% | 1522 |
|
|
2020
Q1 | $78.7K | Buy |
19,103
+442
| +2% | +$2.07K | ﹤0.01% | 2181 |
|
|
2019
Q4 | $89.8K | Sell |
18,661
-281
| -1% | -$1.55K | ﹤0.01% | 2392 |
|
|
2019
Q3 | $115K | Hold |
18,942
| – | – | ﹤0.01% | 2225 |
|
|
2019
Q2 | $123K | Buy |
18,942
+2,602
| +16% | +$18.3K | ﹤0.01% | 2202 |
|
|
2019
Q1 | $116K | Sell |
16,340
-2,190
| -12% | -$14.4K | ﹤0.01% | 2238 |
|
|
2018
Q4 | $90.1K | Hold |
18,530
| – | – | ﹤0.01% | 2328 |
|
|
2018
Q3 | $136K | Hold |
18,530
| – | – | ﹤0.01% | 2264 |
|
|
2018
Q2 | $118K | Hold |
18,530
| – | – | ﹤0.01% | 2237 |
|
|
2018
Q1 | $101K | Buy |
+18,530
| New | +$92.1K | ﹤0.01% | 2294 |
|
|
2017
Q4 | – | Sell |
-34,773
| Closed | -$335K | – | 2535 |
|
|
2017
Q3 | $335K | Buy |
34,773
+5,760
| +20% | +$59.8K | ﹤0.01% | 1957 |
|
|
2017
Q2 | $343K | Hold |
29,013
| – | – | ﹤0.01% | 1968 |
|
|
2017
Q1 | $372K | Hold |
29,013
| – | – | ﹤0.01% | 1862 |
|
|
2016
Q4 | $355K | Buy |
29,013
+2,689
| +10% | +$31.9K | ﹤0.01% | 1969 |
|
|
2016
Q3 | $311K | Sell |
26,324
-3,141
| -11% | -$30.3K | ﹤0.01% | 2043 |
|
|
2016
Q2 | $256K | Sell |
29,465
-3,397
| -10% | -$23.3K | ﹤0.01% | 2157 |
|
|
2016
Q1 | $173K | Buy |
32,862
+4,734
| +17% | +$26.4K | ﹤0.01% | 2253 |
|
|
2015
Q4 | $218K | Hold |
28,128
| – | – | ﹤0.01% | 2210 |
|
|
2015
Q3 | $221K | Buy |
28,128
+710
| +3% | +$6.57K | ﹤0.01% | 2223 |
|
|
2015
Q2 | $248K | Sell |
27,418
-3,070
| -10% | -$31K | ﹤0.01% | 2260 |
|
|
2015
Q1 | $396K | Hold |
30,488
| – | – | ﹤0.01% | 1683 |
|
|
2014
Q4 | $415K | Hold |
30,488
| – | – | ﹤0.01% | 1904 |
|
|
2014
Q3 | $273K | Hold |
30,488
| – | – | ﹤0.01% | 2154 |
|
|
2014
Q2 | $413K | Hold |
30,488
| – | – | ﹤0.01% | 1978 |
|
|
2014
Q1 | $303K | Hold |
30,488
| – | – | ﹤0.01% | 2163 |
|
|
2013
Q4 | $406K | Buy |
30,488
+5,507
| +22% | +$66.9K | ﹤0.01% | 1951 |
|
|
2013
Q3 | $304K | Buy |
24,981
+384
| +2% | +$4.12K | ﹤0.01% | 2096 |
|
|
2013
Q2 | $254K | Buy |
+24,597
| New | +$339K | ﹤0.01% | 2171 |
|
Metropolitan Life Insurance Company (MetLife)'s GNMK Position: Q2 2021 in Review
Metropolitan Life Insurance Company (MetLife) sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 20,221 shares — an estimated $483K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in GNMK in Q2 2013 and held it in 31 quarters. The position peaked at $483K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Metropolitan Life Insurance Company (MetLife) reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 20,221 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $483K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 31 quarters.
- Metropolitan Life Insurance Company (MetLife)'s GenMark Diagnostics, Inc position peaked at $483K in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.